On July 9, Merck announced that it would acquire Verona Pharma, a U.K.-based biotechnology company specializing in the ...

Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or ...

From J&J to BMS, New Jersey pharmaceutical companies continue to expand and transform through M&A, leadership shifts and ...

Verona Pharma has seen its stock price jump by 125 percent year-to-date, closing at $104.74 versus $46.44 in the last trading ...

Abbott Laboratories shares slumped Thursday after the drugmaker narrowed its full-year outlook, even as it posted better-than ...

Merck aims to boost its business by buying Verona Pharma for $10 billion. Through the deal, it will add Ohtuvayre -- a ...

Backed by an initial funding of $15 million from the National Science Foundation, the Regenerative Medicine Engine is the ...

Private equity work is up year-over-year, but tariffs, inflation and valuations continue to be an issue for dealmakers.

Verona Pharma plc (NASDAQ:VRNA)’s shares experienced a boost in July when pharmaceutical giant Merck announced that it would ...

Merck is tackling its looming “Keytruda cliff” with a bold $10 billion acquisition of Verona Pharma. The deal brings ...

Merck & Co. ($MRK) is betting on acquisitions to offset the looming revenue loss from the upcoming patent expiration of ...

Explore last week's key healthcare market trends, top gainers & losers, major deals, Trump's tariff plans, FDA approvals, and significant legal updates.